Roche Holding AG (XSWX:RO) Debt-to-Revenue : 0.51 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:RO Roche Holding AG XSWX:RO
74 GF Score
Price CHF364.20
GF Value CHF271.70
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Roche Holding AG Debt-to-Revenue?

Roche Holding AG XSWX:RO -0.71% 74 Debt-to-Revenue is 0.51 as of Jun. 2026. GuruFocus rates XSWX:RO with a GF Score™ of 74/100 and a GF Value™ of CHF271.70 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Debt-to-Revenue measures a company's ability to pay off its debt.

Roche Holding AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was CHF6,583 Mil. Roche Holding AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was CHF25,222 Mil. Roche Holding AG's annualized Revenue for the quarter that ended in Jun. 2026 was CHF62,904 Mil. Roche Holding AG's annualized Debt-to-Revenue for the quarter that ended in Jun. 2026 was 0.51.

Roche Holding AG Debt-to-Revenue Historical Data

* Premium members only.

The historical data trend for Roche Holding AG's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Roche Holding AG Debt-to-Revenue Chart

Roche Holding AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.52 0.40 0.51 0.58 0.52

Roche Holding AG Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.56 0.58 0.52 0.53 0.51

XSWX:RO vs LLY, JNJ, ABBV: Debt-to-Revenue Comparison

For the Drug Manufacturers - General subindustry, Roche Holding AG's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Roche Holding AG Debt-to-Revenue vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Roche Holding AG's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Roche Holding AG's Debt-to-Revenue falls into.


XSWX:RO
74GF Score
Roche Holding AG XSWX:RO
Debt-to-Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Roche Holding AG Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Roche Holding AG's Debt-to-Revenue for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(4517 + 28674) / 63356
=0.52

Roche Holding AG's annualized Debt-to-Revenue for the quarter that ended in Jun. 2026 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(6583 + 25222) / 62904
=0.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Jun. 2026) Revenue data.

Frequently Asked Questions Learn more about Debt-to-Revenue →
What does a Debt-to-Revenue of 0.51 mean?
Roche Holding AG (XSWX:RO) has a Debt-to-Revenue of 0.51 as of Jun. 2026.
Is Roche Holding AG's Debt-to-Revenue too high?
Roche Holding AG's current Debt-to-Revenue is 0.51. Overall, Roche Holding AG has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roche Holding AG's Debt-to-Revenue compare to LLY and JNJ?
Roche Holding AG's Debt-to-Revenue of 0.51 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Revenue for a Drug Manufacturers company?
A good Debt-to-Revenue depends on the Drug Manufacturers industry context. However, Debt-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Revenue mean?
A high Debt-to-Revenue can signal that a stock is expensive relative to its fundamentals. Roche Holding AG's current Debt-to-Revenue is 0.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roche Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Roche Holding AG (XSWX:RO) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF271.70, compared to a current price of CHF364.20 — trading 34% above its estimated fair value. The current Debt-to-Revenue is 0.51. Roche Holding AG's overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Revenue calculated?
Debt-to-Revenue is calculated from a company's financial statements. For Roche Holding AG (XSWX:RO), the current Debt-to-Revenue is 0.51 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Roche Holding AG (XSWX:RO) Overvalued in 2026?

Based on GuruFocus' analysis, Roche Holding AG stock appears to be overvalued. The current stock price of CHF364.20 is trading 34% above its estimated GF Value™ of CHF271.70. GuruFocus considers Roche Holding AG to be Significantly Overvalued.

Key valuation signals for XSWX:RO:

  • Debt-to-Revenue: 0.51
  • GF Value™: CHF271.70 vs. price of CHF364.20 (34% above fair value)
  • GF Score™: 74/100 with 7 warning signs

No single metric tells the full story. See the XSWX:RO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Roche Holding AG Business Description

Address Grenzacherstrasse 124, Basel, CHE, 4070
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
74GF Score

Get the complete analysis for XSWX:RO

Debt-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF364.20
Price
CHF271.70
GF Value